Myriad Genetics, Inc. (NASDAQ:MYGN) has been assigned an average rating of “Hold” from the thirteen ratings firms that are presently covering the company, MarketBeat.com reports. Four research analysts have rated the stock with a sell rating, two have given a hold rating and six have assigned a buy rating to the company. The average 12-month price target among analysts that have covered the stock in the last year is $39.67.

Several analysts have commented on MYGN shares. Barclays cut shares of Myriad Genetics from an “equal weight” rating to an “underweight” rating and decreased their price target for the stock from $38.00 to $30.00 in a research note on Wednesday, September 5th. Morgan Stanley upgraded shares of Myriad Genetics from an “equal weight” rating to an “overweight” rating and upped their target price for the company from $35.00 to $55.00 in a research report on Wednesday, July 11th. Zacks Investment Research cut shares of Myriad Genetics from a “buy” rating to a “sell” rating in a research report on Monday, August 27th. Bank of America upped their target price on shares of Myriad Genetics from $20.00 to $31.00 and gave the company an “underperform” rating in a research report on Monday, July 16th. Finally, BidaskClub cut shares of Myriad Genetics from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, August 21st.

A number of large investors have recently modified their holdings of the stock. GHP Investment Advisors Inc. grew its stake in Myriad Genetics by 10.3% in the 3rd quarter. GHP Investment Advisors Inc. now owns 58,781 shares of the company’s stock worth $2,704,000 after acquiring an additional 5,491 shares in the last quarter. Bank of Montreal Can grew its stake in Myriad Genetics by 29.2% in the 3rd quarter. Bank of Montreal Can now owns 93,722 shares of the company’s stock worth $4,311,000 after acquiring an additional 21,176 shares in the last quarter. CHICAGO TRUST Co NA bought a new position in Myriad Genetics in the 3rd quarter worth about $230,000. United Services Automobile Association grew its stake in Myriad Genetics by 8.0% in the 2nd quarter. United Services Automobile Association now owns 36,961 shares of the company’s stock worth $1,381,000 after acquiring an additional 2,746 shares in the last quarter. Finally, Northern Trust Corp grew its stake in Myriad Genetics by 2.7% in the 2nd quarter. Northern Trust Corp now owns 1,801,882 shares of the company’s stock worth $67,337,000 after acquiring an additional 47,994 shares in the last quarter.

MYGN stock traded down $1.12 during mid-day trading on Friday, hitting $44.16. The company had a trading volume of 13,764 shares, compared to its average volume of 735,805. The stock has a market cap of $3.26 billion, a P/E ratio of 36.93, a PEG ratio of 3.12 and a beta of 0.51. Myriad Genetics has a 12-month low of $27.23 and a 12-month high of $50.44. The company has a quick ratio of 2.86, a current ratio of 3.19 and a debt-to-equity ratio of 0.01.

Myriad Genetics (NASDAQ:MYGN) last announced its quarterly earnings results on Tuesday, August 21st. The company reported $0.38 EPS for the quarter, topping the consensus estimate of $0.33 by $0.05. The business had revenue of $200.90 million for the quarter, compared to analysts’ expectations of $195.93 million. Myriad Genetics had a net margin of 17.69% and a return on equity of 9.78%. The business’s quarterly revenue was up .7% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.30 EPS. On average, analysts anticipate that Myriad Genetics will post 1.44 EPS for the current fiscal year.

About Myriad Genetics

Myriad Genetics, Inc, a molecular diagnostic company, focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide. The company offers molecular diagnostic tests, including myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; BRACAnalysis CDx, a DNA sequencing test for use as a companion diagnostic with the platinum based chemotherapy agents and poly ADP ribose inhibitor Lynparza; riskScore, a clinically validated personalized medicine tool; GeneSight, a DNA genotyping test to optimize psychotropic drug selection for neuroscience patients; and Tumor BRACAnalysis CDx, a DNA sequencing test that is designed to be utilized to predict response to DNA damaging agents.

Featured Story: What is a Call Option?

Analyst Recommendations for Myriad Genetics (NASDAQ:MYGN)

Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.